Amarin: Is It Time to Test the Waters?

Amarin (NASDAQ:AMRN) released better-than-expected 2019 fourth-quarter results after the closing bell Tuesday. The biopharma's stock promptly dropped by another 0.86%, bringing its total loss for the year to a disappointing 18.4%.